Phase 2 Trial of MEK162 for Advanced Melanoma

Array BioPharma announced data on MEK162 in an ongoing Phase 2 trial of patients with BRAF and NRAS mutated advanced melanoma. The open-label trial is being conducted by Novartis and continues to enroll patients.

Since February 2012, the study has shown that, of the 35 patients with BRAF mutations evaluable for response, eight had partial responses, including two confirmed partial responses and 13 patients demonstrated stable disease. The disease control rate was 60% among these patients with at least two scans. Of the 28 patients with NRAS mutations who were evaluable for response, six had partial responses, including three confirmed partial responses and 13 patients demonstrated stable disease. The disease control rate was 68% among these patients with at least two scans. The median progression-free survival was 3.55 months (95% CI 2–3.81 months) for patients with BRAF mutation and 3.65 months (95% CI 2.53–5.39 months) for patients with NRAS mutations.

MEK162 is a small molecule selective inhibitor of the kinases MEK1 and MEK2.

For more information call (877) MED-CHEM or visit www.arraybiopharma.com.